Leitzel KE - Search Results

1

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.

Kopreski MS, Benko FA, Kwee C, Leitzel KE, Eskander E, Lipton A, Gocke CD. Kopreski MS, et al. Among authors: leitzel ke. Br J Cancer. 1997;76(10):1293-9. doi: 10.1038/bjc.1997.551. Br J Cancer. 1997. PMID: 9374374 Free PMC article.

2

Serum osteoprotegerin levels in healthy controls and cancer patients.

Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. Lipton A, et al. Clin Cancer Res. 2002 Jul;8(7):2306-10. Clin Cancer Res. 2002. PMID: 12114435

3

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.

Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A. Souder C, et al. Cancer. 2006 Nov 15;107(10):2337-45. doi: 10.1002/cncr.22255. Cancer. 2006. PMID: 17048231 Free article. Clinical Trial.

4

Serial serum c-erbB-2 levels in patients with breast carcinoma.

Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Volas GH, et al. Cancer. 1996 Jul 15;78(2):267-72. doi: 10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U. Cancer. 1996. PMID: 8674002 Clinical Trial.

5

Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor.

Leitzel K, Lieu B, Curley E, Smith J, Chinchilli V, Rychlik W, Lipton A. Leitzel K, et al. Clin Cancer Res. 1998 Dec;4(12):3037-43. Clin Cancer Res. 1998. PMID: 9865918

6

Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR.

Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A. Clarke LE, et al. Int J Oncol. 2003 Feb;22(2):425-30. Int J Oncol. 2003. PMID: 12527944

7

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W. Lipton A, et al. Cancer. 2005 Jul 15;104(2):257-63. doi: 10.1002/cncr.21202. Cancer. 2005. PMID: 15952182 Free article.

8

Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W. Lipton A, et al. Cancer. 2007 May 15;109(10):1933-9. doi: 10.1002/cncr.22637. Cancer. 2007. PMID: 17407159 Free article. Clinical Trial.

9

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group. Lipton A, et al. Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430. Cancer. 2010. PMID: 20661914 Free article.

10

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J. Lipton A, et al. Cancer. 2011 Nov 1;117(21):5013-20. doi: 10.1002/cncr.26101. Epub 2011 Mar 31. Cancer. 2011. PMID: 21456017 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page